Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Obicetrapib, Obicetrapib 10mg
obicetrapib+ ezetimibe daily · 2 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily | DRUG | FDC |
| Obicetrapib 10 mg | DRUG | monotherapy |
| Placebo | OTHER | placebo on top of guideline-recommended lipid modifying therapy |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
Obicetrapib is an investigational small molecule being developed for lipid metabolism disorders, including dyslipidemias and lipidemia. It is also being studied in early Alzheimer's disease and hepatic impairment. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
Obicetrapib is being developed by NewAmsterdam Pharma Company N.V., a biopharmaceutical company traded on the stock exchange under the ticker symbol NAMS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various patient populations.
Obicetrapib is currently in Phase 2 clinical development. It has completed five Phase 1 trials and is being investigated for multiple indications, including dyslipidemia and early Alzheimer's disease. The drug remains investigational and has not received regulatory approval.
Obicetrapib has been studied in several clinical trials, including NCT06048302 (hepatic impairment), NCT06081166 (drug-drug interaction with statins), NCT06250205 (combined oral contraceptive interaction), and NCT06547359 (interaction with ezetimibe). These trials have all been completed, with a total enrollment of 9541 participants across all studies.
Obicetrapib is the active drug, and it is also studied in combination formulations such as obicetrapib 10 mg with evolocumab 140 mg every 2 weeks, and obicetrapib 10 mg with ezetimibe 10 mg as a fixed-dose combination. These combinations are being evaluated for their effects on lipid metabolism.
Obicetrapib is a small molecule that targets lipid metabolism pathways. It is being developed to address dyslipidemias, which are imbalances of lipids in the blood. The drug's mechanism involves modulating cholesterol transport, though specific molecular targets have not been disclosed in the available information.